Spero Therapeutics (SPRO) - News Mentions

Sign up to add (SPRO) to your portfolio and access more historical data.

00%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 0 100%
Gilead Sciences
Gilead Sciences
GILD		 0 0%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 0 100%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 0 0%
Anavex Life Sciences
Anavex Life Sciences
AVXL		 0 100%
Spero Therapeutics (NASDAQ:SPRO) Given Overweight Rating at Cantor Fitzgerald
November 18
Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations
November 16
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates
November 14
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
November 14
Spero Therapeutics : Announces Third Quarter 2024 Operating Results and Provides a Business Update Form 8 K
November 14
Spero Therapeutics (SPRO) to Release Quarterly Earnings on Thursday
November 12
Spero Therapeutics (NASDAQ:SPRO) Given New $5.00 Price Target at HC Wainwright
November 8
Q3 EPS Estimate for Spero Therapeutics Lifted by Analyst
November 7
Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024
November 7
TD Cowen Reaffirms Their Buy Rating on Spero Therapeutics (SPRO)
October 31
Spero Therapeutics Announces Operational Restructuring and Strategic Workforce ReductionSpero Therapeutics, Inc. (NASDAQ: SPRO) made significant announcements on October 29, 2024, regarding the restructuring of its operations. The company r
October 31
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
October 29
Spero Therapeutics Restructures Focus on Key R&D Projects
October 28
Spero Therapeutics trading resumes
October 28
Spero Therapeutics trading halted, news pending
October 28
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
October 26

How often is Spero Therapeutics mentioned in the news?

Spero Therapeutics was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Spero Therapeutics performing compared to its industry peers?

Spero Therapeutics underperforms its industry peers when it comes to News Mentions, ranking dead last.

Has there been an increase or decrease in news mentions of Spero Therapeutics in the last month?

There has been no significant change in the number of news mentions for Spero Therapeutics' compared to the last month.

Why is it important to track news mentions for Spero Therapeutics?

By monitoring mentions in the news for Spero Therapeutics, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Spero Therapeutics, ultimately improving their investment strategies.

Sign up and get more insights on Spero Therapeutics.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact